Skip to product information
1 of 1

Preferred Nutrition®

PEA 400 mg

PEA 400 mg

Preferred Nutrition PEA 400 mg is a chronic pain relief formula made from fractionated non-GMO safflower seed oil. Studies have shown that palmitoylethanolamide (PEA), a fatty-acid-like compound, offers analgesic, neuroprotective, and anti-neuroinflammatory benefits. PEA occurs naturally in certain foods and is made within the body as part of the endocannabinoid system. This formula features micronized PEA for improved solubility and absorption.
  • Helps relieve chronic pain
  • Features naturally produced PEA from fractionated non-GMO safflower seed oil
  • Micronized for effective solubility and absorption by the body
  • Provides 1200 mg of PEA per day, the same dose supported by clinical studies

SKU: PN0284

NPN: 80097472

View full details

PEA 400 mg

Additional Information

Recommended Dosage

Recommended adult dose: 3 capsules daily or as directed by a health care practitioner. For use beyond 4 months, consult a health care practitioner

Allergy Information

This product does not contain artificial preservatives, colours, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, corn, egg, fish, shellfish, salt, tree nuts, or genetically modified genes or proteins.


Each capsule contains:
Medicinal ingredient:
Palmitoylethanolamide (PEA) 400 mg

Gelatin capsule (gelatin, purified water), microcrystalline cellulose, vegetable grade magnesium stearate (lubricant), silica, stearic acid.


Consult a health care practitioner if symptoms persist or worsen. Consult a health care practitioner prior to use if you are pregnant or breastfeeding. Keep out of reach of children.


Conigliaro, R., Drago, V., Foster, P.S., et al. (2011). Use of palmitoylethanolamide in the entrapment neuropathy of the median in the wrist. Minerva Med, 102(2), 141-7.

Gatti, A., Lazzari, M., Gianfelice, V., et al. (2012). Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis. Pain Med, 13(9), 1121-30.

Keppel Hesselink, J.M., & Kopsky, D.J. (2015). Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: Efficacy and safety in sciatic pain and carpal tunnel syndrome. J Pain Res, 8, 729-34.

Lang-Illievich, K., Klivinyi, C., Lasser, C., et al. (2023). Palmitoylethanolamide in the treatment of chronic pain: A systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients, 15(6), 1350.

Marini, I., Bartolucci, M.L., Bortolotti, F., et al. (2012). Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain, 26(2), 99-104.